
IGF-1 analog with Long R3 mutation — extended half-life and low affinity to binding proteins. The direct effector of the GH axis.
Not in stock yet. Message us on WhatsApp and we'll let you know as soon as it arrives.
Ranges cited in research literature. Not a usage recommendation. For research use only.
IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of human insulin-like growth factor 1 with two changes: an arginine in place of the glutamate at position 3 (“R3”) and a 13-amino-acid extension at the N-terminus (“Long”), taking the molecule from 70 to 83 amino acids and about 9.1 kDa. It was developed in Australia (GroPep, University of Adelaide) as a cell-culture reagent, which remains its main use: it replaces insulin and IGF-1 in mammalian cell-culture media.
The purpose of the modifications is to reduce affinity for the IGF-binding proteins (IGFBPs), which sequester more than 99% of natural IGF-1 in plasma. By escaping them, LR3 stays free, binds the IGF-1 receptor with similar affinity and proves two to three times more potent in vitro; its circulating half-life is estimated at 20–30 hours, against minutes for free IGF-1. The receptor activates the PI3K–Akt and MAPK pathways, with effects on glucose uptake, protein synthesis and cell proliferation.
There are no clinical trials of IGF-1 LR3 in humans: data come from cell culture, animal models and anecdotal performance use. Native recombinant IGF-1 (mecasermin) is an approved medicine for severe primary IGF-1 deficiency, and its label documents hypoglycemia, lymphoid tissue hypertrophy and the oncologic caution proper to a mitogenic factor; those considerations extrapolate to LR3 with greater uncertainty. It is on the World Anti-Doping Agency list. Renova distributes it for research only.
| Class | Long-acting recombinant analog of human IGF-1 |
| Structure | IGF-1 with Glu3→Arg and a 13-aa N-terminal extension · 83 amino acids · ≈ 9.1 kDa |
| CAS | 946870-92-4 |
| Origin | GroPep / University of Adelaide (Australia); cell-culture reagent |
| Key property | Greatly reduced IGFBP affinity → larger free fraction; in-vitro potency ×2–3 |
| Estimated half-life | 20–30 hours (versus minutes for free IGF-1) |
| Receptor and pathways | IGF-1R → PI3K–Akt, MAPK |
| Regulatory status | Not approved; WADA list (S2) · requires strict cold chain (protein) |
“R3” indicates that the glutamate at position 3 was swapped for an arginine, and “Long” that a 13-amino-acid extension was added to the start of the protein. Together they drastically reduce binding to the IGF carrier proteins, so the molecule circulates free and active for longer.
No. GH is the pituitary hormone that instructs the liver to produce IGF-1; IGF-1 is the final effector of that axis. LR3 acts directly on the IGF-1 receptor, bypassing GH and the regulation the axis imposes. That is why it does not appear alongside secretagogues in the literature.
Its established use is in biotechnology: cell-culture media, where it replaces insulin or IGF-1 to sustain proliferation of mammalian cells. There are no human clinical trials; use in athletic performance is anecdotal and prohibited by the World Anti-Doping Agency.
For the approved recombinant IGF-1 (mecasermin), hypoglycemia, growth of lymphoid tissue and the oncologic caution that accompanies any mitogenic factor are documented. For LR3, with a larger free fraction and longer half-life, those considerations extrapolate with greater uncertainty since no human data exist.
Related reading: IGF-1 LR3: Long-Acting Analog · CJC-1295 + Ipamorelin: The Most-Studied GH Stack
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty